Chinese biotech firms just launched a peptide gel that rebuilds tooth enamel, the hardest substance in the human body that never regenerates naturally. Once cavities form, dentists drill and fill, but this gel changes everything.
The gel contains tiny protein pieces that mimic the natural process babies use to build enamel in the womb. When applied to early cavities, minerals from saliva bond with the peptides and slowly rebuild the damaged surface. Imagine paint that literally becomes part of a wall, growing thicker over weeks. Early-stage decay reverses without any drilling.
The geopolitical drama is intense. The FDA has restricted several Chinese biotech imports citing "data verification concerns," while critics say the delays protect American dental supply companies. Some argue the tensions with China are being used to keep affordable dental innovations out of the US market entirely.
American families spend an average of $685 yearly on dental care, with cavities being the number one issue. Access to this gel abroad costs about $30 per tube, while similar peptide products approved in the US cost hundreds.
Should healthcare innovations transcend trade wars, or is caution justified?
Source: Shanghai Jiao Tong University School of Medicine, 2026
Geen opmerkingen:
Een reactie posten